STOCK TITAN

Ovid Therapeutics Inc - OVID STOCK NEWS

Welcome to our dedicated news page for Ovid Therapeutics (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ovid Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ovid Therapeutics's position in the market.

Rhea-AI Summary
Ovid Therapeutics to participate in two upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.07%
Tags
conferences
-
Rhea-AI Summary
Ovid Therapeutics Inc. (NASDAQ: OVID) reported business updates and financial results for Q2 2023, including the completion of the SAD portion of Phase 1 trial for OV329, an equity investment and collaboration with Graviton Bioscience, and regulatory filings for soticlestat in Lennox-Gastaut syndrome and Dravet syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.42%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.73%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
Ovid Therapeutics Inc

Nasdaq:OVID

OVID Rankings

OVID Stock Data

226.27M
45.10M
15.99%
64.66%
3.96%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About OVID

ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/